Marco Fuel Herrera

Dr. Marco Fuel Herrera

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RORaul Ortiz
Raul Ortiz
FQFrancisco Quiñonero
Francisco Quiñonero
BGBeatriz García-Pinel
Beatriz García-Pinel
MHMarco Fuel Herrera
Marco Fuel Herrera
CMCristina Mesas
Cristina Mesas
JPJose Prados
Jose Prados
The development of drug resistance is one of the main causes of cancer treatment failure. This phenomenon occurs very frequently in different types of cancer, including colon and pancreatic cancers. However, the underlying molecular mechanisms are not fully understood. In recent years, nanomedicine has improved the delivery and efficacy of drugs, and has decreased their side effects. In addition, it has allowed to design drugs capable of avoiding certain resistance mechanisms of tumors. In this article, we review the main resistance mechanisms in colon and pancreatic cancers, along with the most relevant strategies offered by nanodrugs to overcome this obstacle. These strategies include the inhibition of efflux pumps, the use of specific targets, the development of nanomedicines affecting the environment of cancer-specific tissues, the modulation of DNA repair mechanisms or RNA (miRNA), and specific approaches to damage cancer stem cells, among others. This review aims to illustrate how advanced nanoformulations, including polymeric conjugates, micelles, dendrimers, liposomes, metallic and carbon-based nanoparticles, are allowing to overcome one of the main limitations in the treatment of colon and pancreatic cancers. The future development of nanomedicine opens new horizons for cancer treatment.

8 December 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
MHMarco Fuel Herrera
Marco Fuel Herrera
CMCristina Mesas
Cristina Mesas
RMRosario Martínez
Rosario Martínez
RORaul Ortiz
Raul Ortiz
FQFrancisco Quiñonero
Francisco Quiñonero
CMConsolación Melguizo
Consolación Melguizo
Legumes are a highly nutritious source of plant protein, fiber, minerals and vitamins. However, they also contain several bioactive compounds with significant potential benefits for human health. The objectives of this study were to evaluate the antioxidant, antitumor and chemopreventive activity of functional extracts from legumes using raw and germinated flours of six legume species of commercial interest. The methodology carried out consisted on the development of protein hydrolysates, assessment of their antioxidant capacity and in vitro tests on T84, HCT15 and SW480 colorectal cancer (CRC) cell lines. Our results showed a high antitumor activity of protein hydrolysate from M. sativa. Likewise, when combined with 5-Fluorouracile (5-Fu), there was a synergistic effect using extract concentrations from 50 to 175 µg/mL and 5-Fu concentrations from 1.5 to 5 µM. Similarly, the induction effect on detoxifying enzymes by the extracts of M. sativa, germinated V. faba Baraca × LVzt1 and V. narbonensis, which produced a higher induction rate than the positive control sulforaphane (10 µM), should be highlighted. Therefore, incorporating these enzymes into the diet could provide nutritional effects, as well as play an effective role in cancer chemoprevention and therapy.

1 October 2019 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
KDK. Doello
K. Doello
CMC. Mesas
C. Mesas
GPG. Perazzoli
G. Perazzoli
CGC. García-Collado
C. García-Collado
MGM.J. Gándara
M.J. Gándara
JPJ.C. Prados
J.C. Prados
Cabazitaxel is used in the treatment of metastatic prostate cancer. It is not a substrate of P-glycoprotein, which is involved in cellular detoxification of chemotherapeutic agents and in the expulsion of drugs at blood-brain barrier. Our objectives are to test Cabazitaxel in vitro in malignant neural cell lines such as glioblastoma, anaplastic glioma and neuroblastoma, and to find any predictor of response that allows us to select potential responder patients in glioblastoma multiforme and other neural tumors. Cell lines A172 (glioblastoma, p53 wild type), LN229 (glioblastoma, p53 mutated), SF268 (anaplastic glioma, p53 mutated) and SK-N-SH (neuroblastoma, p53 wild type) were cultured in 48-well plates and increasing doses of Cabazitaxel were tested (0.1, 0.5, 1, 5, 10, 25, 50, 100 μM). After 48 hours of treatment, the proliferation values were studied by spectrophotometric assays. Also, gene expression studies of the MMR complex (miss-match repair) were performed by RT-qPCR for the primers of MLH1, MSH2, MSH3, MSH6, PMS2 genes. We also analyzed the expression of CD133 marker by RT-qPCR assays. A PCR study with Bisulfite kit was carried out to detect the promoter methylation of MGMT. IC50 values at 48 hours were 13.76 μM in SF268, 6.77 μM in SK-N-SH, 2.88 μM in LN 229 and 1.34 in A172. The expression values of MMR complex proteins were significantly higher in line A172 (relative value 1), followed by line LN229 (0.25) and negative in lines SK-N-SH and SF268. The methylation of MGMT promoter was positive in lines A172 and LN229. Finally, the expression of CD133 was higher in A172 (0.6), followed by LN229 (0.4), SK-N-SH (0.2) and SF268 (0). Pearson correlation coefficient for the relationship between CD133 expression and IC50 values is -0.96. 1. Glioblastoma, anaplastic glioma and neuroblastoma cell lines have a high sensitivity to Cabazitaxel in vitro. 2. Cell lines with MGMT methylation and MMR expression (A172 and LN 229) are the most sensitive. Of them, line A172 presents a p53 wild type, and therefore, a greater sensitivity to Cabazitaxel. 3. The expression of CD133 correlates inversely with the values of IC50 to Cabazitaxel, and may also be a predictor of response. UGR. Has not received any funding. All authors have declared no conflicts of interest.

20 November 2018 in Química Central
Verified
Journal Article
Closed access
PDF file
MHMarco Fuel Herrera
Marco Fuel Herrera
GJGabriela Gualpa Jácome
Gabriela Gualpa Jácome
ILInés Echeverría Llumipanta
Inés Echeverría Llumipanta
El objetivo del trabajo de investigación fue evaluar la utilidad de la amilasa y lipasa sérica en el diagnóstico ycontrol de tratamiento de pacientes con dolor abdominal agudo de origen pancreático y no pancreático que acudieronal Hospital NORTHOSPITAL de Quito durante el periodo comprendido entre octubre a diciembre del 2015y que presentaron valores elevados de amilasa y lipasa sérica. Las variables edad, sexo, antecedentes patológicosy familiares, motivo de consulta, signos y síntomas, pruebas de laboratorio e imagen, diagnóstico y tratamientofueron obtenidas de las historias clínicas. Para el tratamiento estadístico se emplearon herramientas como: media,frecuencia, sensibilidad, especificidad, valor predictivo positivo (VPP), valor predictivo negativo (VPN), curvasROC, prueba t para muestras relacionadas y ANOVA de un factor. Utilizando pruebas estadísticas de rigor se evidencióque la lipasa sérica presenta una mayor sensibilidad (90,91%) frente a la amilasa (63,3% de sensibilidad)para el diagnóstico de pancreatitis. Ambos parámetros bioquímicos ofrecen un 100% de especificidad. La amilasay lipasa sérica se elevan en el curso de una pancreatitis aguda y en otras patologías no pancreáticas, por lo tantose precisa de otros exámenes de laboratorio y pruebas de imagen para logar un diagnóstico eficaz.

2 September 2026
Verified
Book Chapter
Closed access
PDF file
JTJoe Dylan Cáceres Taya
Joe Dylan Cáceres Taya
SOSamantha Natasha Marcillo Ontaneda
Samantha Natasha Marcillo Ontaneda
ILInés Catalina Echeverría Llumipanta
Inés Catalina Echeverría Llumipanta
MHMarco Fuel Herrera
Marco Fuel Herrera

1 January 2025
Verified
Journal Article
Open access
PDF file
SASantiago Sebastian Ortiz Alvarez
Santiago Sebastian Ortiz Alvarez
VQVictor David Toledo Quelal
Victor David Toledo Quelal
JMJohanna Elizabeth Caicedo Mina
Johanna Elizabeth Caicedo Mina
MHMarco Fuel Herrera
Marco Fuel Herrera
INTRODUCCIÓN. La flebitis es una complicación frecuente y potencialmente grave asociada al uso de catéteres endovenosos periféricos, que compromete la circulación y puede derivar en serias consecuencias clínicas si no se trata oportunamente. OBJETIVO. identificar los factores de riesgo asociados al desarrollo de flebitis en pacientes atendidos en el Hospital Marco Vinicio Iza de Sucumbíos, durante el período de octubre 2023 a abril 2024. MATERIALES Y MÉTODOS. se realizó un estudio observacional transversal con enfoque cuantitativo. La muestra incluyó 100 enfermeros, a quienes se les aplicó un cuestionario y la escala de flebitis recomendada por la Sociedad de Enfermeras de Infusión (INS). RESULTADOS. Dentro de los factores de riesgo el estado nutricional afectó significativamente el desarrollo de flebitis en el 82% de los casos. Asimismo, la edad entre 60 y 65 años presentó una incidencia del 29%. Dentro de las terapias intravenosas, el uso de antibióticos contribuyó en un 58% al desarrollo de flebitis, mientras que los analgésicos se asociaron con un 42%. No obstante, el análisis estadístico no encontró una asociación significativa entre estos factores y el desarrollo de flebitis (p<0.005). CONCLUSIONES. los factores de riesgo significativamente asociados al desarrollo de flebitis fueron el tipo de catéter utilizado y el índice de masa corporal elevado. Es crucial que el personal de enfermería implemente estrategias de prevención y monitoreo, adaptando los protocolos de manejo de catéteres para minimizar riesgos y garantizar la seguridad de los pacientes hospitalizados.